Table 1.
Characteristics of the study subjects
| Control | COPD
|
||
|---|---|---|---|
| GOLD I/II | GOLD III/IV | ||
| Subjects, n | 18 | 37 | 33 |
| Age, years | 69.2±6.2 | 70.1±5.5 | 71.2±6.2 |
| Males/females | 17/1 | 36/1 | 33/0 |
| Smoking, pack-years | 30.5±11.4 | 60.0±27.5* | 61.3±30.5* |
| BMI, kg/m2 | 24.0±3.2 | 23.6±3.2 | 21.0±3.5*,‡ |
| mMRC dyspnea score | 0.1±0.2 | 0.9±0.8* | 1.9±1.0*,‡ |
| FVC, % predicted | 108.3±12.7 | 99.5±16.0 | 73.6±19.0*,‡ |
| FEV1, % predicted | 103.0±13.1 | 70.8±12.2* | 32.6±10.8*,‡ |
| FEV1/FVC, % | 77.5±4.4 | 58.1±9.0* | 35.7±8.7*,‡ |
| IC, L | 2.8±0.5 | 2.3±0.4* | 1.8±0.5*,‡ |
| DLco’, % predicted | 112.3±27.1 | 70.0±25.4* | 43.2±22.6*,‡ |
| 6MWD, m | 510 (470–558) | 450 (400–484)* | 350 (208–402)*,‡ |
| LABA, n | – | 23 | 29 |
| LAMA, n | – | 27 | 33 |
| ICS, n | – | 8 | 11 |
Notes: Data are presented as mean ± SD or median (IQR).
*
p < 0.01 versus control,
‡
p < 0.01 versus GOLD I/II.
Abbreviations: BMI, body mass index; DLco’, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IC, inspiratory capacity; ICS, inhaled corticosteroids; IQR, interquartile range; LABA, long-acting β2 agonist; LAMA, long-acting muscarinic antagonist; mMRC, modified Medical Research Council; 6MWD, 6-minute walking distance.